SCHEMBL13625773

SCHEMBL13625773

O=C(O)CNC(=O)c1nc2cc(-c3cccc(OCc4cccc(F)c4)c3)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.46
EGLN1 Q9GZT9 5/20 0.46
NR4A2 P43354 2/20 0.45
MAOB P27338 2/20 0.45
MAOA P21397 1/20 0.45
MMP13 P45452 2/20 0.43
ROCK2 O75116 1/20 0.43
PRKACA P17612 1/20 0.43
PRKACG P22612 1/20 0.43
PRKACB P22694 1/20 0.43
DHODH Q02127 2/20 0.42
F9 P00740 1/20 0.42
F10 P00742 1/20 0.42
PPARD Q03181 3/20 0.42
FFAR1 O14842 2/20 0.42
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306340 0.93 EGLN1 (0.52) FAAHMRGPRX4EGLN1NR4A2MAOB
SCHEMBL4309249 0.89 EGLN1 (0.51) FAAHEGLN1NR4A2MAOBMAOA
SCHEMBL4309518 0.86 EGLN1 (0.51) EGLN1NR4A2MAOBMAOAMMP13
SCHEMBL4319371 0.86 EGLN1 (0.46) FAAHEGLN1MMP13ROCK2PRKACA
SCHEMBL4310690 0.86 CNR2 (0.46) EGLN1MMP13ROCK2PRKACAPRKACG
SCHEMBL4303188 0.82 EGLN1 (0.52) EGLN1NR4A2MMP13ROCK2PRKACA
SCHEMBL4313430 0.82 EGLN1 (0.67) EGLN1MMP13ROCK2PRKACAPRKACG
SCHEMBL4311056 0.81 EGLN1 (0.48) FAAHEGLN1NR4A2MAOBMAOA
SCHEMBL4309178 0.78 EGLN1 (0.51) FAAHMRGPRX4EGLN1MAOBMMP13
SCHEMBL4307002 0.78 EGLN1 (0.57) FAAHEGLN1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US claimed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 FAAH 396/4885MRGPRX4 3493/4885EGLN1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.